**All Interactions with Rilpivirine (Edurant)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Rilpivirine** | **Effect on Drug Levels** | **Effect on Rilpivirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Acetaminophen[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (others)(Tylenol) | 500 mg x 1 | 150 mg QD | No significant change | Rilpivirine AUC: increased 16%; Cmin: increased 26% | - | - | No dose adjustment necessary |
| Antacids[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Maalox, Mylanta, Riopan, Milk of Magnesia, others) | - | - | - | - | Potentially decreased rilpivirine effects | Decreased gastric acidity leading to impaired drug solubility and absorption | Administer antacids either at least 2 hours before or at least 4 hours after rilpivirine. |
| Atorvastatin[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567) | 40 mg QD | 150 mg QD | Atorvastatin Cmin: decreased 15%; Cmax: increased 35% | No significant change | - | - | No dose adjustment necessary |
| Boceprevir[635](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#635)  (Victrelis) | 800 mg TID | 25 mg QD | No significant change | Rilpivirine AUC: increased 39%; Cmax: increased 15%; Cmin: increased 51% | Possibly increased rilpivirine effects | - | No dose adjustment necessary |
| Chlorzoxazone[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (others)(Parafon Forte) | 500 mg x 1 | 150 mg QD | No significant change | Rilpivirine AUC: increased 25%; Cmin: increased 18%; Cmax: increased 17% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Rilpivirine** | **Effect on Drug Levels** | **Effect on Rilpivirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Darunavir[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (DRV)(Prezista) | 800 mg darunavir with 100 mg ritonavir QD | 150 mg QD | No significant change | Rilpivirine AUC: increased 130%; Cmin: increased 178%; Cmax: increased 79% | Increased rilpivirine effects | - | No dose adjustment necessary |
| Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir[745](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#745)  (Viekira) | paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg twice daily | 25 mg QD | Dasabuvir Cmax ↑ 18%; AUC ↑ 17%; Cmin ↑10%. Ombitasvir AUC ↑ 9%. Paritaprevir Cmin ↑30%, AUC ↑ 23%; Cmin decreased 5% | RPV increased 155%; AUC increased 225%; Cmin increased 262% | Potential for QT interval prolongation with higher concentrations of RPV. | Ritonavir inhibition of rilpivirine (CYP3A4 substrate) | Do not coadminister |
| Didanosine[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (ddI)(Videx) | 400 mg delayed release cap taken 2 hours before rilpivirine | 150 mg QD | No significant change | No significant change | - | - | No dose adjustment necessary; Administer didanosine on an empty stomach and at least 2 hours before or at least 4 hours after rilpivirine (which must be administered with a meal). |
| Dolutegravir[641](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#641)  (Tivicay) | 50 mg QD | 25 mg QD | Dolutegravir Cmin: increased 22% | Rilpivirine Cmin increased 21% | - | - | No dose adjustment necessary |
| Ethinyl estradiol/norethindrone acetate[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (others)(Ortho-Novum) | 0.035 mg QD ethinyl estradiol with 1 mg norethindrone QD | 25 mg QD | Ethinyl estradiol Cmax: increased 17%; Norethindrone: no significant change | No significant change | - | - | No dose adjustment necessary |
| Famotidine[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Pepcid) | 40 mg x 1 taken 12 hours before rilpivirine | 150 mg x 1 | - | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Rilpivirine** | **Effect on Drug Levels** | **Effect on Rilpivirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Famotidine[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Pepcid) | 40 mg x 1 taken 2 hours before rilpivirine | 150 mg x 1 | - | Rilpivirine AUC: decreased 76%; Cmax: decreased 85% | Decreased rilpivirine effects | Decreased gastric acidity leading to impaired drug solubility and absorption | Administer H2-antagonist by at least 12 hours before rilpivirine or at least 4 hours after rilpivirine. |
| Famotidine[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Pepcid) | 40 mg x 1 taken 4 hours after rilpivirine | 150 mg x 1 | - | Rilpivirine Cmax: increased 21% | - | - | No dose adjustment necessary |
| Ketoconazole[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Nizoral) | 400 mg QD | 150 mg QD | Ketoconazole AUC: decreased 24%; Cmin: decreased 66%; Cmax: decreased 15% | Rilvpivirine AUC: increased 49%; Cmin: increased 76%; Cmax: increased 30% | Decreased ketoconazole effects | - | No dose adjustment necessary but monitor for failure of antifungal therapy |
| Lopinavir/ritonavir[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (LPV/r)(Kaletra) | 400/100 mg BID | 150 mg QD | No significant change | Rilpivirine AUC: increased 52%; Cmin: increased 74%; Cmax: increased 29% | Increased rilpivirine effects | - | No dose adjustment necessary |
| Methadone[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Dolophine)(Dolophine) | 60-100 mg QD | 25 mg QD | R-methadone AUC: decreased 16%; Cmin: decreased 22%; S-methadone AUC: decreased 16%; Cmin: decreased 21%; | No significant effect | Potentially decreased methadone effects (eg, withdrawal) | - | Monitor for signs and symptoms of methadone withdrawal; Some patients may need an increase in the methadone dose |
| Omeprazole[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Prilosec)(Prilosec) | 20 mg QD | 150 mg QD | No significant change | Rilpivirine AUC: decreased 40%; Cmin: decreased 33%; Cmax: decreased 40% | Decreased rilpivirine effects | Decreased gastric acidity leading to impaired drug solubility and absorption | Do not coadminister  *Alternative Agents*:  **H2-antagonists if administered at least 12 hours before rilpivirine or at least 4 hours after rilpivirine.** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Rilpivirine** | **Effect on Drug Levels** | **Effect on Rilpivirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Raltegravir[591](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#591)  (RAL)(Isentress) | 400 mg BID | 25 mg QD | Raltegravir Cmin: increased 27% | - | - | - | No dose adjustment necessary |
| Rifabutin[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Mycobutin)(Mycobutin) | 300 mg QD | 150 mg QD | - | Rilpivirine AUC: decreased 46%; Cmin: decreased 49%; Cmax: decreased 35% | Decreased rilpivirine effects | - | Do not coadminister |
| Rifampin[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Rifampicin)(Rifadin) | 600 mg QD | 150 mg QD | No significant change | Rilpivirine AUC: decreased 80%; Cmin: decreased 89%; Cmax: decreased 69% | Decreased rilpivirine effects | Induction of CYP450 3A4 by rifampin | Do not coadminister |
| Sildenafil[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (Viagra) | 50 mg x 1 | 75 mg QD | No significant change | No significant change | - | - | No dose adjustment necessary |
| Simeprevir[675](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#675)  (Olysio) | 150 mg QD x 11 days | 25 mg QD x 11 days | No significant change | Rilpivirine Cmin increased 25% | - | - | No dose adjustment necessary |
| Sofosbuvir[659](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#659)  (Sovaldi) | 400 mg x 1 | 25 mg QD | Sofosbuvir Cmax increased 21% | - | - | - | No dose adjustment necessary |
| Sofosbuvir/velpatasvir[751](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#751)  (Epclusa) | 400 mg/100 mg | 25 mg | - | Rilpivirine Cmin decreased 7% | - | - | No dose adjustment necessary |
| Telaprevir[629](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#629)  (Incivek) | 750 mg Q8H | 25 mg QD | No significant change | Rilpivirine AUC: increased 78%; Cmin: increased 93%; Cmax: increased 49% | - | - | No dose adjustment necessary |
| Tenofovir disoproxil fumarate[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=205&post=4#567)  (TDF)(Viread) | 300 mg QD | 150 mg QD | Tenofovir AUC: increased 23%; Cmin: increased 24%; Cmax: increased 19% | No significant change | Potentially increased tenofovir effects | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 567: | Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011. |
| 591: | Crauwels H, Stevens M, De La Rosa G, et al. Absence of pharmacokinetic interaction between the NNRTI rilpvirine and the integrase inhibitor raltegravir [paper# 617]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012. Seattle, WA. |
| 629: | Kakuda T, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial [abstract O-18]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012. Barcelona, Spain. |
| 635: | Rhee E, Feng H-P, Xuan F, et al. Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine [paper #537]. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, Georgia. |
| 641: | Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; Sept 2013. |
| 659: | Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2013. |
| 675: | Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013. |
| 745: | Viekira [package insert]. North Chicago, IL: AbbVie Inc.; 2016. |
| 751: | Epclusa [package insert]. Foster City, CA: Gilead Sciences, 2016. |